MMP-7

MMP-7 Molekülinformation

Englischer Name	Matrilysin	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	Matrin，Matrix metalloproteinase-7，Pump-1 protease，Uterine metalloproteinase，MPSL1，PUMP1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Matrilysin
Target-Alias	Matrin，Matrix metalloproteinase-7，Pump-1 protease，Uterine metalloproteinase，MPSL1，PUMP1
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

MMP-7 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (1)Cynomolgus (1)
Etikett
His Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
MM7-H5249	Human	HEK293	Human MMP-7 / PUMP1 Protein, His Tag (Pro-form)				In den Warenkorb legen
MM7-C53H3	Cynomolgus	CHO	Cynomolgus MMP-7 Protein, His Tag (Pro-form, HPLC verified)				In den Warenkorb legen

Gesamtmenge2

MMP-7 Molekülhintergrund

MMP-7 (matrilysin), the smallest zinc-dependent endopeptidase in the MMP family, lacks a hemopexin domain but features a catalytic zinc-binding motif (HEXXHXXGXXH) critical for degrading extracellular matrix (ECM) components, including collagens III/IV/V, elastin, and proteoglycans. Activated via proteolytic cleavage (e.g., by MMP-3), it promotes tissue remodeling in wound healing while driving pathological processes such as tumor invasion (via E-cadherin degradation and Wnt/β-catenin activation) and fibrosis (via β-catenin-mediated renal damage). Overexpressed in epithelial cancers, MMP-7 correlates with metastasis but paradoxically shows protective genetic variants in some contexts. It also processes non-ECM substrates like TNF-α and Fas ligand, amplifying inflammation and oncogenesis. In fibrotic diseases, elevated serum MMP-7 predicts progression, serving as a diagnostic biomarker. Therapeutic strategies targeting MMP-7, including inhibitors and monoclonal antibodies, highlight its dual roles as both a driver of ECM disruption and a modulator of immune-tumor interactions.